Many multiple myeloma patients can become resistant to an important class of myeloma drugs called proteasome inhibitors. Researchers found that expression of MUC20 could help predict how sensitive or resistant patients would be to proteasome inhibitors and found that MUC20 protein could be potentially impacted by an already FDA-approved drug offered by Amgen.

Learn more from Dr. Muhamad Baljevic of the University of Nebraska Medical Center about how this new drug is being used in a Phase I/II clinical trial to see if patients who have become resistant to carfilzomib can overcome that resistance by adding this new drug to the mix. These new c-MET inhibitors could have broader use in myeloma combinations.

Thanks to our episode sponsor, Celgene Corporation.

Myeloma Crowd Radio: Muhamed Baljevic, MD, University of Nebraska Medical Center

Share

Embed